RankingsPricing
  1. US-listed companies
  2. Kezar Life Sciences, Inc.
  3. Raw

Kezar Life Sciences, Inc.KZR

Market cap
$45.73M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-23-35-42-55-68-102-84
Depreciation and amortization1122111
Stock-based compensation2458141813
Amortization of premiums and discounts on marketable securities01-0-2175
Amortization of Debt Issuance Costs and Discounts---0000
Impairment loss of property and equipment-----0-
Operating Lease, Impairment Loss-----32
Other-----0-0-0
Prepaid expenses and other current assets------4-0
Other assets-0---05-3
Accounts payable and accrued liabilities120126-3
Operating lease asset and liabilities----002
Net cash used in operating activities-21-30-37-42-59-82-74
Purchases of property and equipment1100220
Purchases of marketable securities11910222615633218091
Maturities of marketable securities36123169128242258172
Proceeds from sale of equipment0----0-
Net cash provided by (used in) investing activities-8420-56-28-917680
Proceeds from issuance of common stock under employee stock incentive plans-002110
Net cash provided by financing activities78010011312810
Effect of exchange rate changes on cash and cash equivalents-0-00-0-0-0-0
Net increase (decrease) in cash and cash equivalents-27-9642-22-56
Capital Expenditures Incurred but Not yet Paid0--00--
Par value of common stock upon cashless exercise of prefunded warrants-----0-
Cash paid for interest---0111